Bladder Cancer Lights Get Fancy Cysto Rename from FDA
Published Date: 8/17/2026
Proposed Rule
Summary
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Manufacturers Shift from PMA to 510(k)
If this proposal is finalized, companies that make these cystoscopic systems will no longer have to submit a premarket approval (PMA) and instead will submit a 510(k) premarket notification and receive clearance before marketing. FDA says the 510(k) pathway is less burdensome and more cost-effective than a PMA, may shorten review timelines, and manufacturers may use FDA-authorized predetermined change control plans (PCCPs) to implement certain future modifications without a new 510(k).
Potentially Faster Patient Access
FDA is proposing to reclassify these devices from class III to class II so they would be cleared through 510(k) rather than approved through PMA. FDA says a 510(k) typically results in a shorter premarket review timeline than a PMA, which may provide more timely patient access to cystoscopic systems used as an adjunct to detect bladder cancer.
Special Controls to Mitigate Device Risks
FDA proposes to impose special controls for these cystoscopic systems as class II devices to mitigate identified risks, including false positive/negative results, device failure or malfunction, electrical/thermal/light injuries, interference with other devices, infection/cross-contamination, and adverse tissue reactions. FDA states these special controls, together with general controls, would provide a reasonable assurance of safety and effectiveness.
Devices Identified as Prescription Products
FDA proposes that the device type be identified as prescription devices and, if finalized, they would be subject to prescription labeling requirements under 21 CFR 801.109. That means these cystoscopic systems must be labeled and distributed only under a prescription, consistent with other prescription medical devices.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-16724, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities-May 2026
This document announces the Agency's receipt of and solicits public comment on initial filings of pesticide petitions requesting the establishment or modification of regulations for residues of pesticide chemicals in or on various commodities. The Agency is providing this notice in accordance with the Federal Food, Drug, and Cosmetic Act (FFDCA). EPA uses the month and year in the title to identify when the Agency compiled the petitions identified in this notice of filing. Unit II. of this document identifies certain petitions received in 2025 and 2026 that are currently being evaluated by EPA, along with information about each petition, including who submitted the petition and the requested action.
Next: 2026-16729, Medical Devices; Classification of Accessories Distinct From Other Devices; Proposed List of Accessories Suitable for Class I; Request for Comments
As required by the FDA Reauthorization Act of 2017 (FDARA), the Food and Drug Administration (FDA or Agency) has identified a list of accessories for which the Agency believes general controls alone are sufficient to provide reasonable assurance of safety and effectiveness, making them appropriate for class I classification. FDA is publishing this document proposing to classify these accessories into class I and distinct from other devices, as well as seeking public comment in accordance with procedures established by FDARA. This document does not represent FDA's final determination with respect to the proposed accessories listed in this document.